Maverix Medical

Maverix Medical

Maverix Medical was formed through the architecture of Ajax Health, the KKR-backed medtech platform led by Duke Rohlen, and focuses entirely on the lung cancer care continuum. The firm functions less as a traditional fund and more as an operating company that acquires and integrates device and diagnostic businesses. Its key portfolio companies include Thoracent, a minimally invasive pleural effusion management developer, and the diagnostics arm built upon the acquisition of Cirrus Bio, co-founded by David Mallery, which develops molecular tools for early cancer triage. The strategy spans three operational pillars: diagnostics, interventional devices, and palliative care. Its diagnostics program, led by David Mallery and Scott Morris, is developing blood-based assays to triage high-risk patients alongside low-dose CT screening. The Serpex Steerable Portfolio provides articulating endobronchial instruments for targeting off-airway nodules. The Thoracent unit, run by Brian Lynch, supplies devices for pleural effusion management and airway patency. This structure mimics a vertically integrated medtech operator rather than a diversified pool of passive LP commitments, concentrating capital in one therapeutic area across the United States. Maverix is anchored by the executive and operational team of Ajax Health, which includes CFO Doug Koo, COO David Beylik, and CCO Carla Jung. The broader platform has previously exited companies to Medtronic and Boston Scientific. David Mallery, who sold Cirrus Bio into Maverix, co-founded several precision oncology companies and is a member of YPO. The firm operates out of Menlo Park and draws on a medical advisory board of pulmonary physicians. In its most recent known corporate move, Maverix acquired Cirrus Bio to add molecular diagnostic capability to its device portfolio, integrating its genomics lab and AI-driven biomarker discovery engine into the platform. Unlike a standard venture firm, Maverix is a single-disease, full-stack company builder. It owns the operating entities outright and places key Ajax partners like Duke Rohlen, Aftab Kherani, and David Beylik directly into management roles. This blurs the line between financial sponsor and operator, creating a holding-company model that pushes product development through a centralized commercial organization rather than relying on arm's-length portfolio oversight.